An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo
Eli Lilly’s (LLY.N) recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday.
The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
While, adults who are commercially insured without coverage may be eligible to pay as low as $550 for a 1-month prescription.
The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk’s (NOVOb.CO) Wegovy in addressing record obesity rates.
Lilly’s drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used “off-label” for weight loss while the obesity approval was pending.
Reporting by Manas Mishra and Khushi Mandowara in Bengaluru; Editing by Arun Koyyur
